Contour Neurovascular System™ ContiNued Access Investigational Device EXempTion (IDE) Trial (NEXT Trial)
A legfontosabb adatok
- Ki végzi
- Cerus Endovascular, Inc.
- Hol
- Buffalo, Charleston, Kansas City, Park Ridge, Philadelphia, Raleigh, Seattle és Stony Brook (Egyesült Államok)Mind a 9 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 250 fő, tervezett
- Kezdés
- 2025. jún. 10.
- Várható befejezés
- 2030. jan.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Contour Neurovascular System Treatment Attempt
- A regiszteradat frissítve
- 2026. március 31.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with one wide-necked, sac-shaped brain aneurysm that needs treatment. The aneurysm may have burst or not. They will be treated with the Contour Neurovascular System.
- Életkor
- 18 to 75 years
- Nem
- All sexes
- A betegség stádiuma
- One burst or unburst brain aneurysm needing treatment. It is sac-shaped and sits where a brain artery splits. Neck 2 to 10 mm, width 2 to 10.5 mm. Wide-necked: neck ≥ 4 mm or dome/neck ratio < 2. If burst, the person must be neurologically stable with a Hunt & Hess Score of I, II or III.
- Korábbi kezelés
- The aneurysm must not already hold other devices, such as coils, that could get in the way. Treatment must be possible with Contour alone, with no other implanted devices.
A részvétel fő kizáró okai
- Kidney failure (unless on dialysis) or creatinine > 2.00 mg/dl or > 182 μmol/L
- Cannot take blood thinners or anti-platelet drugs, or cannot stop blood thinners such as warfarin
- Stroke or stroke-like symptoms in the prior 60 days, or other bleeding in the brain within 90 days
- Modified Rankin Scale score ≥ 2 before the aneurysm was found or burst
- Pregnant, breastfeeding or planning pregnancy in the next 2 years
A regiszter feltételei, szó szerint
Mind a 26 feltétel megnézéseKevesebb
Ki vehet részt
- Patient is 18-75 years of age at the time of screening
- Patient has a single ruptured or unruptured IA requiring treatment. If the patient has an additional IA requiring treatment, the additional IA must not require treatment within 60 days after the index procedure
- The target IA must have the following characteristics:; Saccular morphology; Located at a bifurcation in the anterior or posterior circulation; Aneurysm neck diameter between 2 and 10 mm and aneurysm equatorial diameter between 2 and 10.5 mm; Wide-necked, defined as neck size ≥ 4 mm or a dome/neck ratio < 2
- Patient may be treated with Contour without the use of additional implanted devices
- Patient is able to comply with all aspects of the screening, evaluation, treatment, and the post-procedure follow-up schedule
- Patient or legally authorized representative has signed and dated an institutional review board (IRB)/Ethics Committee (EC)-approved written informed consent prior to initiation of any study procedures; FOR PATIENTS WITH UNRUPTURED ANEURYSM
- Patient meets the criteria outlined in the "Guidelines for the Management of Patients With Unruptured Intracranial Aneurysms" as published by the AHA/ASA\^6; FOR PATIENTS WITH RUPTURED ANEURYSM
- Patient meets the criteria outlined in the "Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association" as published by the AHA/ASA.\^6
- Patient must be neurologically stable with Hunt \& Hess Score of I, II or III; (\^6: 6 https://www.ahajournals.org/doi/full/10.1161/STR.0000000000000070)
Ki nem vehet részt
- Anatomy or physiology considered unsuitable for endovascular treatment with the Contour device by the implanting physician and/or the Patient Selection Committee
- Target IA contains other devices/implants (e.g., coils) that could interfere with the correct placement of the Contour device
- Anticoagulation medications (e.g., warfarin) that cannot be discontinued
- Conditions placing them at high risk for ischemic stroke or had exhibited ischemic symptoms such as transient ischemic attacks, minor strokes, or stroke-in-evolution within the prior 60-days
- Modified Rankin Scale (mRS) score ≥ 2 prior to presentation or rupture (as applicable)
- Subject is enrolled in another device or drug study in which participation could confound study results
- Subject has a known, untreatable hypersensitivity to contrast dye, iodine, or any component of the treatment device
- Vascular disease or other vascular anomaly that precluded the necessary access to the aneurysm for use of the study device
- Any circulatory, neurovascular, cardiovascular, or neurologic conditions that can result in unstable neurological symptoms (e.g., multiple sclerosis, established seizure disorder)
- Subarachnoid hemorrhage (SAH) from a non-index aneurysm or any other intracranial hemorrhage within 90 days
- Physical, neurologic or psychiatric conditions which precluded his/her ability to comply with all aspects of the screening, evaluation, treatment, and the post-procedure follow-up schedule
- Life expectancy of less than 2 years due to an illness or condition other than the index intracranial aneurysm
- Contraindication to anticoagulants or anti-platelet medications
- Acute / chronic renal failure (unless on dialysis) or creatinine > 2.00 mg/dl or > 182 μmol/L
- Stenosis of the target IA's parent vessel is >50%
- Clinical, angiographic or computed tomography (CT) evidence of vasospasm, vasculitis, an intracranial tumor (except small meningioma) or any other intracranial vascular malformations on presentation
- Pregnant, breastfeeding or planning pregnancy in the next 2 years
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 75 év között vagy?
Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.
- University at Buffalo NeurosurgeryBuffalo, Egyesült ÁllamokContact: Ellen CarlRésztvevőt keres
- Medical University of South CarolinaCharleston, Egyesült ÁllamokContact: Melza GoffinetRésztvevőt keres
- University of Kansas Medical CenterKansas City, Egyesült ÁllamokContact: Jason GorupRésztvevőt keres
- Advocate Aurora HealthPark Ridge, Egyesült ÁllamokContact: Demetrius Lopes, MD (principal investigator)Résztvevőt keres
- Thomas Jefferson UniversityPhiladelphia, Egyesült ÁllamokContact: Danna SmithRésztvevőt keres
- University of PennsylvaniaPhiladelphia, Egyesült ÁllamokContact: Leah CoghlanRésztvevőt keres
- NC Heart and Vascular Research, LLCRaleigh, Egyesült ÁllamokContact: Jennifer VanduineRésztvevőt keres
- Swedish Neuroscience InstituteSeattle, Egyesült ÁllamokContact: Laura JohnsonRésztvevőt keres
- Stony Brook UniversityStony Brook, Egyesült ÁllamokContact: Marlene BaumeisterRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this clinical trial is to collect additional data to demonstrate if the Contour Neurovascular System (CNS) is a safe and effective treatment of wide-necked, saccular, intracranial aneurysms.
A teljes eredeti leírásKevesebb
Participants will:
Undergo treatment with the Contour Neurovascular System Complete follow-up visits at 1month, 12months, and 24 months, following their procedure Report any adverse events to their study team
A vizsgálat csoportja
- Treatment Attempt with the Contour Neurovascular SystemA vizsgált kezelés
Subjects for which the index procedure (implant of the Contour Neurovascular System) was attempted.
Kezelés: Contour Neurovascular System Treatment Attempt
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Contour Neurovascular System™ ContiNued Access Investigational Device EXempTion (IDE) Trial
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT06693011: ki vehet részt
- A regiszteradat frissítve
- 2026. március 31.